The phase Ib, Keynote-012 trial demonstrated an ORR of 18.5% with durable responses amongst patients with triple negative breast cancer, whose tumour was PD-L1 positive (Combined positive score (CPS) ≥ 1%), treated with pembrolizumab monotherapy [85]. This evidence concerns the gene CD274 and neoplasm.